Get access

The association of metabolic syndrome and psoriasis: a population- and hospital-based cross-sectional study


  • Conflicts of interest

    • Iben M. Miller has received a grant under the Industrial PhD Programme (Co-financed grants by the Danish Agency for Science, Technology and Innovation and LEO Pharma. Christina Ellervik, Gabrielle Vinding, Kian Zarchi and Kristina Ibler have no conflict of interest. Kim Mark Knudsen is an employee at LEO Pharma. Gregor Jemec reports receiving consulting fees from Abbott Laboratories, Astra-Zeneca, MSD, Novartis, Pfizer and Dumex-Alpharma, lecture fees from Abbott laboratories, Galderma, Pfizer and Roche, and grant support from Abbott Laboratories, Pfizer, Photocure and LEO Pharma- receiving equipment on loan from Michelson Diagnostics- and receiving reimbursement for travel expenses from Abbott Laboratories, Galderma and Photocure.
  • Funding sources

    • The GESUS study received funding from the following: Johan and Lise Boserup Foundation; Trygfonden; Det Kommunale Momsfond; Johannes Fogs Foundation; Region Zealand Foundation; Naestved Hospital; Naestved Hospital Foundation; The National Board of Health.
  • All authors had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The results have not been presented officially prior to submission. Contents of the manuscript have not been previously published and are not currently submitted elsewhere.



Psoriasis (PS) has been suggested to be associated with the metabolic syndrome (MetS) in numerous studies with conflicting results. The vast majority of previous data were based on PS subjects from hospitals, and when based on data from the general population the PS subjects were often identified in insurance health databases. Furthermore, many studies used a single method approach, e.g. self-reported diagnosis.


We have therefore investigated a possible association between PS and MetS on PS subjects from the hospital as well as the general population using combined methods, i.e. self-reported diagnosis, physical examinations and blood samples.


A population- and hospital-based cross-sectional study of the possible association between PS and MetS.


Thirty-six hospital PS subjects, 860 population PS subjects and 14 016 non-PS subjects were identified. The odds ratios (ORs) for hospital PS subjects and population PS subjects vs. population non-PS subjects, respectively, were 5.14 (2.47–10.69) and 1.29 (1.09–1.53) for MetS, 4.55 (1.91–10.85) and 1.16 (0.85–1.59) for diabetes, 1.92 (0.87–4.22) and 1.00 (0.86–1.17) for hypertension, 4.34 (1.86–10.10) and 1.15 (1.00–1.34) for hypertriglyceridaemia, 3.88 (1.96–7.69) and 1.19 (1.01–1.42) for hypoHDL, 5.77 (2.89–11.52) and 1.19 (1.00–1.41) for general obesity and 2.92 (1.45–5.88) and 1.34 (1.16–1.55) for abdominal obesity. Obesity acted as a possible confounder. A uniform pattern of higher ORs for hospital PS subjects when compared to population PS subjects was observed. The severity and duration of PS did not seem to affect the results. As this is a cross-sectional study we cannot demonstrate causality.


The data suggested an association between PS and MetS as well as its individual parameters on a hospital-based level, with the exception of hypertension. On a population-based level the associations were only significant for MetS, hypoHDL and abdominal obesity.